SETBP1 and myelodysplastic syndrome: This meta-analysis suggests that SETBP1 mutations are strongly associated with a poorer survival in patients with MDS (HR = 1.808, 95% CI (1.218–2.685), P = 0.001) and CMML (HR = 2.223, 95% CI (1.493–3.308), P<0.001), but not in patients with CNL (HR = 1.773, 95% CI (0.877–3.582), P = 0.111).